# Accent Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accent-therapeutics

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.accenttx.com
- Total disclosed funding: $111M
- Latest round: Series C (Jan 24, 2024)
- Investors on record: 13

## About

Based in Massachusetts, US, and founded in 2017 by Robert A. Copeland, Accent Therapeutics, Inc., a.k.a. Accent Therapeutics operates as a biotechnology company that develops oncology-focused therapies using epi transcriptomics. The therapy modifies the chemical composition of RNA cells to regulate proteins that focus on cellular growth and differentiation. In January 2024, Accent Therapeutics, Inc. raised USD 75.66 million in series C funding led by Mirae Asset Global Investments, with participation from Bristol-Myers Squibb Company, Johnson & Johnson Innovation, Mirae Asset Capital, Mirae Asset Venture Investment, AbbVie Biotech Ventures, Atlas Venture, DROIA Ventures, EcoR1 Capital, GV, The Column Group, The Mark Foundation for Cancer Research, and Timefolio Capital. The Series C funding values Accent Therapeutics, Inc. at USD 183.85 million post-money.

Accent Therapeutics develops small-molecule therapies targeting RNA-modifying proteins (RMPs) to treat various cancers. The company’s platform leverages expertise in cancer biology to identify and inhibit intracellular enzyme targets, focusing on critical areas for drug discovery. The company's pipeline includes first-in-class and best-in-class programs designed to address significant unmet medical needs. The firm’s approach prioritizes biomarker-driven oncology indications, aiming to generate new investigational new drugs (INDs) every 12–18 months.

The company plans to use its proceeds from January 2024 funding to advance its research and development for small-molecule precision cancer therapy.

## Funding rounds

- Series C, Jan 24, 2024, $76M — Atlas Venture, Mirae Asset Global Investments, Johnson & Johnson Innovation, The Column Group, GV, Bristol-Myers Squibb Company, AbbVie Ventures, EcoR1 Capital, Mirae Asset Venture Investment, Droia Ventures, Timefolio Capital, Mark Foundation for Cancer Research, Mirae Asset Capital
- Series B, Apr 23, 2020, $25M — Atlas Venture, The Column Group, GV, AbbVie Ventures, EcoR1 Capital, Droia Ventures, Timefolio Capital, Mark Foundation for Cancer Research
- Series A, May 18, 2018, $10M — Atlas Venture, The Column Group, EcoR1 Capital

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A, Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B, Series C
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series B, Series C
- Timefolio Capital — Series B, Series C
- Mark Foundation for Cancer Research — Series B, Series C
- Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- Bristol-Myers Squibb Company — Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series C
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series C